🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 28/11/2014 | 115,65 | 120,91 | 115,65 | 117,88 | +2,16% | 4,55% | 1.121.800 |
| 26/11/2014 | 114,68 | 116,27 | 113,89 | 115,39 | +1,05% | 2,08% | 1.061.100 |
| 25/11/2014 | 114,17 | 114,99 | 113,63 | 114,19 | +0,34% | 1,19% | 1.786.100 |
| 24/11/2014 | 111,55 | 113,96 | 111,32 | 113,80 | +2,15% | 2,37% | 1.085.900 |
| 21/11/2014 | 114,43 | 114,43 | 110,62 | 111,40 | -1,32% | 3,33% | 1.300.100 |
| 20/11/2014 | 112,88 | 113,00 | 109,34 | 112,89 | +0,08% | 3,24% | 2.557.400 |
| 19/11/2014 | 111,03 | 118,17 | 111,00 | 112,80 | +1,59% | 6,46% | 1.988.500 |
| 18/11/2014 | 111,17 | 112,60 | 109,87 | 111,04 | -0,52% | 2,46% | 1.815.100 |
| 17/11/2014 | 110,80 | 112,28 | 110,26 | 111,62 | +0,25% | 1,82% | 930.500 |
| 14/11/2014 | 113,46 | 114,23 | 110,05 | 111,34 | -1,22% | 3,68% | 1.127.500 |
| 13/11/2014 | 116,70 | 116,75 | 111,85 | 112,72 | -3,39% | 4,20% | 1.240.700 |
| 12/11/2014 | 117,21 | 117,48 | 114,45 | 116,68 | -0,69% | 2,59% | 833.800 |
| 11/11/2014 | 116,94 | 117,97 | 116,07 | 117,49 | +0,47% | 1,62% | 856.300 |
| 10/11/2014 | 116,16 | 117,56 | 114,00 | 116,94 | +0,87% | 3,06% | 1.131.700 |
| 07/11/2014 | 116,83 | 117,19 | 113,79 | 115,93 | -1,16% | 2,91% | 1.307.200 |
| 06/11/2014 | 112,43 | 117,61 | 111,85 | 117,29 | +5,11% | 5,12% | 1.533.600 |
| 05/11/2014 | 114,67 | 114,99 | 110,91 | 111,59 | -2,20% | 3,56% | 1.099.300 |
| 04/11/2014 | 112,32 | 115,52 | 111,91 | 114,10 | +0,99% | 3,21% | 1.196.300 |
| 03/11/2014 | 112,64 | 113,35 | 111,61 | 112,98 | +0,30% | 1,54% | 1.046.800 |
| 31/10/2014 | 113,75 | 114,98 | 111,02 | 112,64 | +1,61% | 3,48% | 1.664.600 |
| 30/10/2014 | 109,21 | 111,82 | 108,61 | 110,85 | +0,86% | 2,94% | 1.398.400 |
| 29/10/2014 | 113,83 | 113,92 | 108,02 | 109,91 | -3,65% | 5,18% | 2.447.500 |
| 28/10/2014 | 112,37 | 115,24 | 111,78 | 114,07 | +2,22% | 3,08% | 2.169.900 |
| 27/10/2014 | 109,34 | 111,78 | 107,86 | 111,59 | +1,53% | 3,59% | 1.204.900 |
| 24/10/2014 | 108,12 | 110,25 | 107,07 | 109,91 | +1,68% | 2,94% | 939.300 |
| 23/10/2014 | 107,03 | 109,55 | 106,33 | 108,09 | +1,81% | 3,01% | 1.261.200 |
| 22/10/2014 | 109,36 | 111,00 | 106,00 | 106,17 | -1,84% | 4,57% | 1.539.700 |
| 21/10/2014 | 105,86 | 110,91 | 104,51 | 108,16 | +3,24% | 6,05% | 1.891.100 |
| 20/10/2014 | 102,51 | 105,00 | 101,85 | 104,77 | +2,36% | 3,07% | 1.178.600 |
| 17/10/2014 | 101,13 | 102,95 | 99,26 | 102,35 | +1,08% | 3,65% | 1.825.800 |